Our results clearly imply that PD-L1 and PD-L2 differentially control induction of T- and Breg-cell responses after MCAO, thus suggesting that selective targeting PD-L1 and PD-L2 might represent a valuable therapeutic strategy in stroke. The gene discussed is PDCD1LG2; the disease is stroke disorder.